Targeting FGF21 for the treatment of nonalcoholic steatohepatitis
| Autor: | Xavier Palomer, Javier Pizarro-Delgado, Mohammad Zarei, Manuel Vázquez-Carrera, Emma Barroso |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Drug Liver Cirrhosis FGF21 media_common.quotation_subject Inflammation Disease Toxicology digestive system 03 medical and health sciences 0302 clinical medicine Fibrosis Non-alcoholic Fatty Liver Disease Nonalcoholic fatty liver disease Medicine Humans Triglicèrids Obesity Triglycerides Liver diseases media_common Pharmacology business.industry Malalties del fetge nutritional and metabolic diseases medicine.disease Inflamació digestive system diseases Fibroblast Growth Factors 030104 developmental biology medicine.anatomical_structure Hepatocyte Cancer research Obesitat medicine.symptom Steatosis business 030217 neurology & neurosurgery |
| Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona |
| Popis: | Nonalcoholic steatohepatitis (NASH), the severe stage of nonalcoholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis with inflammation, hepatocyte injury, and different degrees of fibrosis. Although NASH affects 2–5% of the global population, no drug has been specifically approved to treat the disease. Fibroblast growth factor 21 (FGF21) and its analogs have emerged as a potential new therapeutic strategy for the treatment of NASH. In fact, FGF21 deficiency favors the development of steatosis, inflammation, hepatocyte damage, and fibrosis in the liver, whereas administration of FGF21 analogs ameliorates NASH by attenuating these processes. We review mechanistic insights into the beneficial and potential side effects of therapeutic approaches targeting FGF21 for the treatment of NASH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|